This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by FINNERTY, F. A. Articles by CHUPKOVICH, V. Search for Related Content PubMed PubMed Citation Articles by FINNERTY, F. A., JR. Articles by CHUPKOVICH, V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHLORTHALIDONE RESERPINE

(Circulation. 1965;32:13.)
© 1965 American Heart Association, Inc.

---

Value of Chlorthalidone Plus Reserpine in Moderately Severe and Severe Hypertension

A Two-Year Study

FRANK A. FINNERTY JR. M.D.¹; NIKOS KAKAVIATOS M.D.¹; VICTOR CHUPKOVICH M.D.¹

¹ From the Department of Medicine, Georgetown University School of Medicine and Cardiovascular Research Laboratory, Georgetown University Medical Division of the District of Columbia General Hospital, Washington, D. C.

One hundred nine patients with moderately severe hypertension and 12 patients with severe hypertension received the combination of 50 mg. of chlorthalidone plus 0.25 mg. of reserpine combined in a single tablet (Regroton) administered once daily for an average duration of 2 years.

The ease of administration (one tablet daily), the effectiveness (78-per cent good response), the lack of development of drug resistance over a 2-year period, and the small incidence of side effects would seem to make the combination of 50 mg. of chlorthalidone plus 0.25 mg. of reserpine the ideal treatment for most patients with hypertension. If a more rapid reduction in arterial pressure is indicated, as in patients with severe hypertension, or if a satisfactory therapeutic response has not been observed in 3 to 4 months in patients with moderately severe hypertension, suboptimal doses of other antihypertensive agents may be added.